CR site: Tips for improving subject recruitment

August 2009
Clinical Trials Administrator;Aug2009, Vol. 7 Issue 8, p92
The article presents tips from Patricia Larrabee, chief executive officer (CEO) of Rochester Clinical Research Inc. on improving clinical trial recruitment. Larrabee says that the clinical research (CR) site will provide advertising to venues that have been proven to attract the demographic of subjects they seek. She suggests the social networking sites such as Facebook and MySpace for a study that will recruit younger adults. She stresses that recruiting should be prioritized at CR sites.


Related Articles

  • Antisoma to discontinue Phase II breast cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p4 

    The article reports on the move of Great Britain-based biopharmaceutical firm Antisom PLC to discontinue the Phase II trial of its AS1402 in breast cancer. It states that decision of the company came after the meeting of the trials Data Monitoring Committee and concluded that the trial will not...

  • Argos Raises $35.2M in Series C for Cancer and HIV Candidates. Young, Donna // BioWorld Today;4/24/2008, Vol. 19 Issue 80, p1 

    The article reports on the amount raised by Argos Therapeutics in a Series C financing to support Phase II clinical trials of its renal cell carcinoma and HIV candidates, which uses the firm's RNA-loaded dendritic cell-based immunotherapy technology, called Arcelis. The financing, according to...

  • InDex Moves Kappaproct into Phase III Ulcerative Colitis Trial. Sheridan, Cormac // BioWorld International;3/7/2012, Vol. 17 Issue 10, p1 

    The article reports that Kappaproct, the lead drug candidate of InDex Pharmaceuticals AB, will be moved into a European Phase III trial in patients with chronic active ulcerative colitis who did not respond to other therapies. The COLLECT study will investigate the ability of Kappaproct to...

  • Biotech: Yakatan Has Hope for Drug.  // San Diego Business Journal;10/27/2003, Vol. 24 Issue 43, p10 

    Presents the views of Gerald Yakatan, president and CEO of Avanir Pharmaceuticals Inc. on the clinical trials of AVP13358 for the treatment of excess immunoglobulin E and Th 2 in the U.S.

  • NO GOING BACK. Colman, Alan // New Scientist;10/22/2005, Vol. 188 Issue 2522, p61 

    Presents an interview with Alan Colman, CEO of ES Cell International Pte. Ltd. Description of the reasons for which he left Great Britain; Experiences of Colman while working in Singapore; Views of Colman on setting up clinical trials in Singapore.

  • People news.  // Applied Clinical Trials;Feb2005, Vol. 14 Issue 2, p62 

    This article presents information on the recruitment of executives in the clinical research industry in several countries. Jim Volpe is 13 Research's new global director of quality improvement. Jere Hardy was hired by Endpoint Research to lead its data management services. CllnPhone has added...

  • Hearing Focuses on Life Sciences Funding.  // BioWorld Today;11/17/2008, Vol. 19 Issue 224, p6 

    The article reports on the claims by Rachel King, chief executive officer (CEO) of Glycomimetrics Inc., that biomedical research and drug development are important in driving the nation's economy. During a hearing about investing in biomedical research, she says the indirect effects of increased...

  • Clinical Trials: A Retrospective.  // Applied Clinical Trials;Sep2010, Vol. 19 Issue 9, p8 

    The article offers information on several topics offered by the periodical "Applied Clinical Trials" in the clinical trials industry.

  • CE/CME questions.  // IRB Advisor;Jun2007, Vol. 7 Issue 6, p72 

    A quiz concerning medical research and clinical trials is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics